Company intelligence / Profile preview
Seraxis
- Ownership
- Private
- Development stage
- Preclinical
Overview
Seraxis has developed a proprietary process to manufacture human pancreatic endocrine organoids from a single donor pancreas. Their lead candidate, SR‑02, will enter clinical testing with immunosuppressive therapy for severe recurrent hypoglycemia in type 1 diabetes patients. Preclinical data show long-term normalization of blood glucose in animal models. A follow-on program aims to deliver an immune-evasive version for broader use without chronic immunosuppression.
- Therapeutic areas
- Endocrinology
- Modalities
- Stem cell-derived organoids (pancreatic endocrine cell clusters)Cell therapyImmune-evasive cell encapsulation technology
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Seraxis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Seraxis.